Novavax, Inc. (NVAX)

9.23 -0.13 (-1.39%) USD  |  NASDAQ  |  May 07, 16:00
9.32 +0.09 (+0.98%) Pre-Market: 08:28
More

Novavax Research and Development Expense (Annual) : 336.82M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for NVAX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Merck & Co., Inc. 12.51B
Pfizer Inc. 10.25B
Moderna, Inc. 2.917B
Johnson & Johnson 14.83B
Intellia Therapeutics, Inc. 379.09M